Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement.
Delphi
brodalumab
consensus
psoriasis
statement
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
18 May 2023
18 May 2023
Historique:
received:
20
03
2023
revised:
05
05
2023
accepted:
16
05
2023
medline:
27
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against interleukin-17RA that has been approved for the treatment of moderate-to-severe psoriasis in Europe. We developed a Delphi consensus document focused on brodalumab for the treatment of moderate-to-severe psoriasis. Based on published literature and their clinical experience a steering committee drafted 17 statements covering 7 domains specific to the treatment of moderate-to-severe psoriasis with brodalumab. A panel of 32 Italian dermatologists indicated their level of agreement using a 5-point Likert scale (from 1 = "strongly disagree" to 5 = "strongly agree") using an online modified Delphi method. After the first round of voting (32 participants), positive consensus was reached for 15/17 (88.2%) of the proposed statements. Following a face-to-face virtual meeting, the steering committee decided that 5 statements would form "main principles" and 10 statements formed the final list. After a second round of voting, consensus was reached in 4/5 (80%) of the main principles and 8/10 (80%) for consensus statements. The final list of 5 main principles and 10 consensus statements identify key indications specific to the use of brodalumab in the treatment of moderate-to-severe psoriasis in Italy. These statements aid dermatologists in the management of patients with moderate-to-severe psoriasis.
Identifiants
pubmed: 37240650
pii: jcm12103545
doi: 10.3390/jcm12103545
pmc: PMC10219103
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Leo Pharma
ID : Unconditional contribution
Références
Br J Dermatol. 2017 Mar;176(3):741-751
pubmed: 27106510
J Dermatolog Treat. 2018 Dec;29(8):754-760
pubmed: 29565190
Br J Dermatol. 2017 Jul;177(1):47-62
pubmed: 27580411
Dermatol Ther (Heidelb). 2022 Jun;12(6):1289-1302
pubmed: 35672564
J Drugs Dermatol. 2020 Feb 01;19(2):138-143
pubmed: 32129957
Arthritis Rheum. 2005 Feb 15;53(1):83-92
pubmed: 15696575
Drug Des Devel Ther. 2017 Jul 07;11:2065-2075
pubmed: 28744098
Expert Opin Biol Ther. 2021 Sep;21(9):1299-1310
pubmed: 34114515
Dermatol Ther (Heidelb). 2021 Dec;11(6):2027-2042
pubmed: 34606048
Dermatology. 2021;237(1):46-55
pubmed: 31962340
N Engl J Med. 2012 Mar 29;366(13):1181-9
pubmed: 22455412
Br J Dermatol. 2020 Dec;183(6):1037-1048
pubmed: 32286683
Ital J Dermatol Venerol. 2022 Feb;157(Suppl. 1 to No. 1):1-78
pubmed: 35262308
Psoriasis (Auckl). 2016 Mar 29;6:33-40
pubmed: 29387592
Clin Cosmet Investig Dermatol. 2019 Jul 10;12:509-517
pubmed: 31372022
Ital J Dermatol Venerol. 2022 Dec;157(6):469-479
pubmed: 35785927
Cells. 2020 Oct 14;9(10):
pubmed: 33066433
Postepy Dermatol Alergol. 2020 Apr;37(2):168-173
pubmed: 32489349
Dermatol Ther (Heidelb). 2022 Jun;12(6):1367-1381
pubmed: 35590037
J Invest Dermatol. 2012 Oct;132(10):2466-2469
pubmed: 22622425
J Am Acad Dermatol. 2017 Aug;77(2):372-374
pubmed: 28711089
J Am Acad Dermatol. 2015 Mar;72(3):436-439.e1
pubmed: 25553889
Lancet Oncol. 2012 Feb;13(2):e77-82
pubmed: 22300862
Chest. 2010 Mar;137(3):674-91
pubmed: 20202949
Drugs Context. 2019 Apr 17;8:212570
pubmed: 31024633
J Drugs Dermatol. 2023 Apr 1;22(4):419-422
pubmed: 37026879
J Am Acad Dermatol. 2019 Sep;81(3):857-859
pubmed: 31078609
Eur J Intern Med. 2013 Jul;24(5):385-92
pubmed: 23333028
Br J Dermatol. 2018 Jul;179(1):13-14
pubmed: 30156285
Br J Dermatol. 2016 Aug;175(2):273-86
pubmed: 26914406
Indian J Dermatol. 2017 Mar-Apr;62(2):113-122
pubmed: 28400628
J Eur Acad Dermatol Venereol. 2017 May;31(5):774-790
pubmed: 28244153
Lancet. 2015 Sep 5;386(9997):983-94
pubmed: 26025581
Dermatol Ther (Heidelb). 2020 Aug;10(4):615-621
pubmed: 32533554
J Dermatolog Treat. 2022 Feb;33(1):531-534
pubmed: 32419527
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):450-457
pubmed: 32662540
Br J Dermatol. 2019 Sep;181(3):450-458
pubmed: 30729500
Br J Dermatol. 2021 Sep;185(3):585-594
pubmed: 33792895
Dermatol Ther. 2020 Nov;33(6):e14351
pubmed: 32981222
J Drugs Dermatol. 2022 Feb 1;21(2):146-150
pubmed: 35133106
J Invest Dermatol. 2013 Jan;133(1):17-26
pubmed: 22673731
J Am Acad Dermatol. 2021 Apr;84(4):1169-1171
pubmed: 33221464
Life (Basel). 2022 Dec 07;12(12):
pubmed: 36556415
J Eur Acad Dermatol Venereol. 2018 Aug;32(8):1305-1313
pubmed: 29512200
Br J Dermatol. 2020 Apr;182(4):880-888
pubmed: 31276189
J Am Acad Dermatol. 2020 Feb;82(2):352-359
pubmed: 31175909
N Engl J Med. 2015 Oct;373(14):1318-28
pubmed: 26422722
Dermatol Ther (Heidelb). 2021 Dec;11(6):1917-1929
pubmed: 34626330
J Immunol. 2014 Apr 15;192(8):3828-36
pubmed: 24646743
Am Health Drug Benefits. 2016 Dec;9(9):504-513
pubmed: 28465778
Int J Mol Sci. 2017 Nov 16;18(11):
pubmed: 29144382
Br J Dermatol. 2019 Feb;180(2):306-314
pubmed: 30328108
Circulation. 2003 Jul 1;107(25):3133-40
pubmed: 12796126
Lancet Reg Health Eur. 2021 Nov 22;13:100266
pubmed: 34950923
JAMA Dermatol. 2020 Mar 1;156(3):258-269
pubmed: 32022825
Clin Cosmet Investig Dermatol. 2009 Feb 19;2:9-13
pubmed: 21436964
J Dermatolog Treat. 2022 Feb;33(1):261-265
pubmed: 32250714
An Bras Dermatol. 2014 Mar-Apr;89(2):312-7
pubmed: 24770509
J Eur Acad Dermatol Venereol. 2020 Jan;34(1):39-46
pubmed: 31465593
Dermatology. 2017;233(5):366-377
pubmed: 29258093
JAMA Dermatol. 2015 Jan;151(1):87-94
pubmed: 25471223
J Am Acad Dermatol. 2018 Aug;79(2):277-286.e10
pubmed: 29609013
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2461-2498
pubmed: 33349983
Dermatol Ther. 2021 Nov;34(6):e15106
pubmed: 34418225
Dermatology. 2008;217(4):365-73
pubmed: 18810241
Biomedicines. 2022 Jun 23;10(7):
pubmed: 35884790
J Dermatolog Treat. 2018 Sep;29(6):557-568
pubmed: 29323542
Ann Rheum Dis. 2021 Feb;80(2):185-193
pubmed: 33106286
J Cutan Med Surg. 2022 Jul-Aug;26(1_suppl):3S-23S
pubmed: 35819172
JAMA Neurol. 2020 Aug 1;77(8):937-946
pubmed: 32421186
Dermatol Ther. 2020 Nov;33(6):e14338
pubmed: 32975343